Literature DB >> 30058153

Pregnancy and birth outcomes in a Danish nationwide cohort of women with autoimmune hepatitis and matched population controls.

Lisbet Grønbaek1,2, Hendrik Vilstrup1, Peter Jepsen1,2.   

Abstract

BACKGROUND: Many patients with autoimmune hepatitis are women of fertile age. Some concerns of these patients are related to pregnancy. AIM: To conduct a nationwide study on risk of miscarriage, birth rate, and birth outcomes in women with autoimmune hepatitis.
METHODS: From Danish healthcare registries, 1994-2015, we identified 179 births in 103 women with autoimmune hepatitis, 70 of which were first-time singleton births, and 1623 births in 1051 age-matched women (population controls), 662 of which were first-time singleton births. We calculated the risk of miscarriage and the birth rate after autoimmune hepatitis diagnosis in women with autoimmune hepatitis and controls. We used logistic regression to compare the odds of adverse birth outcomes (preterm birth, small for gestational age, congenital malformations and stillbirth) between women with autoimmune hepatitis and controls, adjusting for maternal age and smoking habits.
RESULTS: The risk of miscarriage was similar in women with autoimmune hepatitis and controls: risk ratio 1.17 (95% confidence interval 0.81-1.68). The first-time birth rate, including singleton and multiple births, per 1000 person-years in women with autoimmune hepatitis was 37 (95% confidence interval 29-46), in controls 32 (95% confidence interval 30-35). Age at first-births was similar in women with autoimmune hepatitis and controls. Women with autoimmune hepatitis had an increased risk of preterm birth (adjusted odds ratio 3.19, 95% confidence interval 1.53-6.64) and small for gestational age babies (adjusted odds ratio = 3.20, 95% confidence interval 0.33-31.29), but not of congenital malformations (adjusted odds ratio = 1.27, 95% confidence interval 0.48-3.34) or stillbirth. Birth outcomes did not differ in autoimmune hepatitis patients on or off immunosuppression, and with or without cirrhosis.
CONCLUSIONS: In Danish women with autoimmune hepatitis, fertility was unaffected. They had an increased risk of preterm birth and small for gestational age children, but not of congenital malformations or stillbirth.
© 2018 John Wiley & Sons Ltd.

Entities:  

Mesh:

Year:  2018        PMID: 30058153     DOI: 10.1111/apt.14925

Source DB:  PubMed          Journal:  Aliment Pharmacol Ther        ISSN: 0269-2813            Impact factor:   8.171


  4 in total

1.  Outcomes of pregnancy in autoimmune hepatitis: A population-based study.

Authors:  Connie W Wang; Joshua Grab; Michele M Tana; Roxanna A Irani; Monika Sarkar
Journal:  Hepatology       Date:  2021-12-05       Impact factor: 17.298

Review 2.  Indian National Association for the Study of the Liver-Federation of Obstetric and Gynaecological Societies of India Position Statement on Management of Liver Diseases in Pregnancy.

Authors:  Anil Arora; Ashish Kumar; Anil C Anand; Pankaj Puri; Radha K Dhiman; Subrat K Acharya; Kiran Aggarwal; Neelam Aggarwal; Rakesh Aggarwal; Yogesh K Chawla; Vinod K Dixit; Ajay Duseja; Chundamannil E Eapen; Bhabadev Goswami; Kanwal Gujral; Anoop Gupta; Ankur Jindal; Premashish Kar; Krishna Kumari; Kaushal Madan; Jaideep Malhotra; Narendra Malhotra; Gaurav Pandey; Uma Pandey; Ratna D Puri; Ramesh R Rai; Padaki N Rao; Shiv K Sarin; Aparna Sharma; Praveen Sharma; Koticherry T Shenoy; Karam R Singh; Shivaram P Singh; Vanita Suri; Nirupama Trehanpati; Manav Wadhawan
Journal:  J Clin Exp Hepatol       Date:  2019-03-06

3.  Congenital Malformations in Denmark: Considerations for the Use of Danish Health Care Registries.

Authors:  Anne Broe; Per Damkier; Anton Pottegård; Jesper Hallas; Mette Bliddal
Journal:  Clin Epidemiol       Date:  2020-12-15       Impact factor: 4.790

4.  Systematic review with meta-analysis: outcomes of pregnancy in patients with autoimmune hepatitis.

Authors:  Tengfei Si; Zhenlin Huang; Robert Hegarty; Yun Ma; Michael A Heneghan
Journal:  Aliment Pharmacol Ther       Date:  2022-04-08       Impact factor: 9.524

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.